Market Research

Proliferative Diabetic Retinopathy Market (Drug Class: Anti-VEGF Agents and Corticosteroids; and Mode of Administration: Injectable, Oral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2023-2031

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 170 Pages Transparency Market Research Pvt. Ltd. January, 2024 TNPR18580321
Best Price Guarantee
Price from $5,795
Length 170 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date January, 2024
SKU TNPR18580321

Proliferative Diabetic Retinopathy Market (Drug Class: Anti-VEGF Agents and Corticosteroids; and Mode of Administration: Injectable, Oral, and Others) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2023-2031


Proliferative Diabetic Retinopathy Market – Scope of Report

TMR’s report on the global proliferative diabetic retinopathy market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global proliferative diabetic retinopathy market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global proliferative diabetic retinopathy market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the proliferative diabetic retinopathy market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global proliferative diabetic retinopathy market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global proliferative diabetic retinopathy market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global proliferative diabetic retinopathy market.

The report delves into the competitive landscape of the global proliferative diabetic retinopathy market. Key players operating in the global proliferative diabetic retinopathy market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global proliferative diabetic retinopathy market profiled in this report.

Key Questions Answered in Global proliferative diabetic retinopathy Market Report
  • What is the sales/revenue generated by proliferative diabetic retinopathy across all regions during the forecast period?
  • What are the opportunities in the global proliferative diabetic retinopathy market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Proliferative Diabetic Retinopathy Market – Research Objectives and Research Approach

The comprehensive report on the global proliferative diabetic retinopathy market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global proliferative diabetic retinopathy market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global proliferative diabetic retinopathy market.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Proliferative Diabetic Retinopathy Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Anti-VEGF Agents
6.3.2. Corticosteroids
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Mode of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Mode of Administration, 2017–2031
7.3.1. Injectable
7.3.2. Oral
7.3.3. Others
7.4. Market Attractiveness Analysis, by Mode of Administration
8. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Proliferative Diabetic Retinopathy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Proliferative Diabetic Retinopathy Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Anti-VEGF Agents
10.3.2. Corticosteroids
10.4. Market Value Forecast, by Mode of Administration, 2017–2031
10.4.1. Injectable
10.4.2. Oral
10.4.3. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Mode of Administration
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Proliferative Diabetic Retinopathy Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Anti-VEGF Agents
11.3.2. Corticosteroids
11.4. Market Value Forecast, by Mode of Administration, 2017–2031
11.4.1. Injectable
11.4.2. Oral
11.4.3. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Mode of Administration
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Proliferative Diabetic Retinopathy Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Anti-VEGF Agents
12.3.2. Corticosteroids
12.4. Market Value Forecast, by Mode of Administration, 2017–2031
12.4.1. Injectable
12.4.2. Oral
12.4.3. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Mode of Administration
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Proliferative Diabetic Retinopathy Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Anti-VEGF Agents
13.3.2. Corticosteroids
13.4. Market Value Forecast, by Mode of Administration, 2017–2031
13.4.1. Injectable
13.4.2. Oral
13.4.3. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Mode of Administration
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Proliferative Diabetic Retinopathy Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Anti-VEGF Agents
14.3.2. Corticosteroids
14.4. Market Value Forecast, by Mode of Administration, 2017–2031
14.4.1. Injectable
14.4.2. Oral
14.4.3. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Mode of Administration
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Genentech, Inc.
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Novartis AG
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Regeneron Pharmaceuticals, Inc.
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Pfizer Inc.
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Merck KGaA
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Cipla Inc.
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. AbbVie Inc.
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Bausch Health Companies Inc.
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Santen Pharmaceutical Co., Ltd.
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Alimera Sciences
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Intas Pharmaceuticals Ltd.
15.3.11.1. Company Overview
15.3.11.2. Product Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings